Figures & data
Figure 1 Structure of the novel SLC34A2-ROS1 fusion gene.
Notes: A is the novel fusion gene and is different from the other two SLC34A2-ROS1 fusion (B and C) variants. In the COSMIC database, two SLC34A2-ROS1 fusion forms were found (B and C). In the novel SLC34A2-ROS1 fusion, 3′UTR of SLC34A2 in exon 13 was disrupted and inverted to connect a position of intronic_e32_e31 of ROS1.
Abbreviations: COSMIC, Catalogue Of Somatic Mutations In Cancer; 3′ UTR, 3′ untranslated region.
Figure 2 Accuracy verification of the novel SLC34A2-ROS1 fusion by Sanger sequencing.
Notes: (A) Based on the results of the next-generation sequencing, we designed a primer pair based on the ROS1 gene’s breakpoint downstream and left to the SLC34A2 gene’s upstream breakpoint; (B) the mutations in the sample DNA were sequenced by Sanger sequencing and the breakpoints in the next-generation sequencing are identical.
Figure 3 Computed tomography and positron emission tomography images of the right lower lobe.
Notes: Mediastinum, upper and lower bilateral clavicle area, left armpit, and lung lymph node metastases at treatment initiation (March 2016; A). After treatment with crizotinib for 2 months (May 2016; B), the metastatic lymph nodes had disappeared, with the metabolism returning to normal; 11 months later (February 2017; C). No new tumor metastases were found in other organs and bones in other parts of the body. The patient’s overall recovery was good; the primary lesion was relieved, the lymph node metastasis had disappeared, and the metabolism was normal.
